Dr Westin discusses the results of the phase III DUO-E/GOG-3041/ENGOT-EN10 trial, which evaluated the combination of durvalumab with standard first-line chemotherapy (carboplatin and paclitaxel - CP), with or without olaparib, in patients with advanced endometrial cancer.
The study included patients with newly diagnosed FIGO Stage III/IV or recurrent endometrial cancer who were previously untreated with systemic therapies.
In the intent-to-treat population, both the CP plus durvalumab and CP plus durvalumab plus olaparib groups demonstrated statistically significant and clinically meaningful improvements in progression free survival (PFS) compared to the CP alone group.
Interim overall survival data showed a trend toward benefit for the combination groups as well. Subgroup analysis by mismatch repair (MMR) status showed that both MMR-deficient (dMMR) and MMR-proficient (pMMR) patients benefited from the combination treatments. In pMMR patients, the addition of olaparib further enhanced the PFS benefit.
She concludes by noting that the DUO-E/GOG-3041/ENGOT-EN10 trial met both primary endpoints, demonstrating significant and clinically meaningful improvements in PFS by adding durvalumab to CP and maintaining durvalumab with or without olaparib compared to CP alone. Furthermore, olaparib provided additional PFS benefit in patients with pMMR disease.